GILD
Gilead SciencesNASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-05-08
As of May 8, 2026, GILD has a composite score of 9.4 and a signal labeled as "mixed." The company momentum score increased significantly by 44.8 points to 16.7, while the composite insight score rose by 10.4 points to 9.4. The scores reflect medium confidence and moderate risk, with key drivers including macroeconomic factors related to labor, rates, growth, and inflation. This analysis is provisional.
Price
Daily closes from AlphaVantage. Earnings/event dots are placed inline.
Factor signals
Read top-to-bottom: thesis (is this a strong company over a 1–3 year hold), watch flags (has something changed worth re-reading), and position context (how violent might the path be). Each pill is a parallel diagnostic — never aggregated into a single score.
Thesis
— is this a strong company over a 1–3 year hold?Why this rank
- Direction share0.16
- Slope (norm)0.56
- Bonus0.00
Why this rank
Trailing four: 2024-Q3, 2025-Q1, 2025-Q2, 2025-Q3
Why this rank
Watch
— has something changed worth re-reading?Buyback / dividend activity on weakening fundamentals — historically a value-trap pattern (48% T+1y positive return vs 69% baseline in IT 2024-26).
Why this setup
EPS estimate $2.10 → $1.94 (-7.8% / 30d). 3 raised, 6 cut, 19 covering analysts.
0 upgrades, 0 downgrades / 30d, 4 maintained. 73% of analysts rate Buy.
2 PT revisions / 30d. Avg target 21.8% above current price.
2 positive, 1 negative / 30d. See F4 management tile for the event list.
F4 · Management deep-dive — recent events, stated priorities, guidance track record
Recent 8-K events
8 material events in the last 24 months — top 5 listed below.
- 2025-11-19GILD — officer changeimpact 0.36
- 2025-08-14GILD — Principal Accounting Officer transitionimpact 0.27
- 2025-10-06GILD — litigation filedimpact 0.23
- 2026-02-23GILD — M&A activity — Entry into a Material Definitive Agreement Agreement and Plan of Mergerimpact 0.22
- 2026-04-28GILD — acquisition announcedimpact 0.20
Stated priorities
3 priorityies extracted from earnings transcripts (as of 2026-05-08).
- 1.Complete acquisition of Arcellxcapital allocationmixed41% progress
4/28: “Gilead completed the acquisition of Arcellx on April 28, 2026.”
Why this status
Stated in 2 of last 2 quarters. The acquisition of Arcellx was completed on April 28, 2026, as planned. This strategic move is expected to bolster Gilead's growth trajectory. The completion aligns with management's stated priority, indicating successful execution of the acquisition strategy.
- 2.Increase product sales excluding Veklurygrowthbehind11% progress
2/10: “Gilead expects product sales excluding Veklury to be between $29,000 and $29,400 million.”
Why this status
Stated in 2 of last 2 quarters. Product sales excluding Veklury are expected to increase from $28,400 million in 2025-Q4 to a range of $29,000 to $29,400 million in 2026. This indicates a positive trajectory towards achieving growth in non-Veklury product sales, although the status remains behind expectations.
- 3.Maintain strong overall product salesgrowthbehind11% progress
5/7: “Gilead raised its full year revenue guidance to $30,000 to $30,400 million.”
Why this status
Stated in 2 of last 2 quarters. Gilead raised its full year revenue guidance from $28,700 million in 2025-Q4 to a range of $30,000 to $30,400 million in 2026. Despite the increase in guidance, the status remains behind expectations, indicating challenges in maintaining strong overall product sales.
Guidance track record
Insufficient guidance history for this ticker.
Position context
— how violent might the path be while I hold it?Why this risk level
Recent vol — 30d annualized 22%; 252d 27%.
Drawdown — Max 1y −18%. Bad day move −3%.
Beta to sector ETF (XLV) — 0.97 over 1y.
Liquidity — score 100/100.
Sub-scores — vol 54/100, drawdown 65/100, beta 97/100, earnings vol —.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive — historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only — describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-05-08.
What changed
The most important moves since the prior daily snapshot.
- score change · company_momentum_scoreseverity 75
Company momentum rose by 44.8 points (from -28.1 to 16.7).
- score change · composite_insight_scoreseverity 21
Composite insight rose by 10.4 points (from -1.0 to 9.4).
As of May 8, 2026, GILD's company momentum score rose by 44.8 points, increasing from -28.1 to 16.7. The composite insight score also improved by 10.4 points, moving from -1.0 to 9.4. The overall signal transitioned to "mixed," and the confidence label is now "medium." The inputs indicate that the changes are provisional.
as of 2026-05-08
Management scorecard
How management runs the business — capital, margins, balance sheet, and how reliably they guide and deliver.
What management is focused on
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
- #1
Complete acquisition of Arcellx
Capital allocationNew since 2026-05-04Finalize the acquisition of Arcellx to enhance strategic growth.
MixedStated in 2 of last 2 quarters. The acquisition of Arcellx was completed on April 28, 2026, as planned. This strategic move is expected to bolster Gilead's growth trajectory. The completion aligns with management's stated priority, indicating successful execution of the acquisition strategy.
41%CEO/CFO:“Gilead completed the acquisition of Arcellx on April 28, 2026.”Multiple sourcesSource dated 2026-04-28Stated 2 of last 8 quartersFirst seen 2026-05-04Show history (2)
- 2026-Q1Multiple sources
“Gilead completed the acquisition of Arcellx.”
- 2025-Q4Multiple sources
“Gilead entered into an Agreement and Plan of Merger with Arcellx.”
- #2
Increase product sales excluding Veklury
GrowthNew since 2026-05-04Focus on boosting sales of products other than Veklury to drive growth.
BehindStated in 2 of last 2 quarters. Product sales excluding Veklury are expected to increase from $28,400 million in 2025-Q4 to a range of $29,000 to $29,400 million in 2026. This indicates a positive trajectory towards achieving growth in non-Veklury product sales, although the status remains behind expectations.
11%CEO/CFO:“Gilead expects product sales excluding Veklury to be between $29,000 and $29,400 million.”Multiple sourcesSource dated 2026-02-10Stated 2 of last 8 quartersFirst seen 2026-05-04Show history (2)
- 2026-Q1Multiple sources
“Product sales excluding Veklury $29,000 to $29,400 million.”
- 2025-Q4Multiple sources
“Product sales excluding Veklury $28,400 to $28,700 million.”
- #3
Maintain strong overall product sales
GrowthNew since 2026-05-04Ensure robust sales performance across all product lines.
BehindStated in 2 of last 2 quarters. Gilead raised its full year revenue guidance from $28,700 million in 2025-Q4 to a range of $30,000 to $30,400 million in 2026. Despite the increase in guidance, the status remains behind expectations, indicating challenges in maintaining strong overall product sales.
11%CEO/CFO:“Gilead raised its full year revenue guidance to $30,000 to $30,400 million.”Multiple sourcesSource dated 2026-05-07Stated 2 of last 8 quartersFirst seen 2026-05-04Show history (2)
- 2026-Q1Multiple sources
“Raised full year revenue guidance to $30,000 to $30,400 million.”
- 2025-Q4Multiple sources
“Product sales $28,400 to $28,700 million.”
How this stock is priced
Two ways to read price: against peers in the same business, and against the company's own history.
Roughly priced in line with peers.
Cheaper than its own typical valuation.
P/E over the last 5 years
62 monthly pointsHow this compares
A side-by-side read on composite, valuation, and risk versus peers.
| Stock | Composite | Valuation | Risk |
|---|---|---|---|
GILD Gilead Sciences | +9.4 | fair | moderate |
LLY Lilly (Eli) | +21 | full | moderate |
JNJ Johnson & Johnson | +18 | full | low |
ABBV AbbVie | +12 | fair | low |
UNH UnitedHealth Group | +24 | fair | elevated |
Risk — how this stock moves
What a normal day looks like, what a bad day looks like, and the worst the last year has thrown at it.
What could change this view
Conditional scenarios — if X happens, the score would shift by about Y points. These are not predictions.
- If next-quarter guidance is raised (currently LOWERED as of 2026-05-07)+16 pts
- If health_care sector trend rises from +0.06 into 'improving' (>= +0.20)+5.0 pts
- If labor state reverses from -0.31 (negative) to +0.31 (positive)-6.8 pts
- If health_care sector trend falls from +0.06 into 'weakening' (<= -0.20)-5.0 pts
- If rates state reverses from -0.37 (negative) to +0.37 (positive)-2.9 pts
Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-05-071d agoItem 2.02
Results of Operations and Financial Condition. On May 7, 2026 , Gilead Sciences, Inc., a Delaware corporation (“Gilead”), announced its financial results for the quarter ended March 31, 2026. A copy of the press release is filed as Exhibit 99.1 to this report. Gilead has presented certain financial information in accordance with U.S. generally accepted accounting principles (“GAAP”) and also on a non-GAAP basis. Management believes this non-GAAP information is useful for investors, when consi…
earnings preannouncementnegativescore 77 - 2026-04-2810d agoItem 8.01
Other Events. As previously disclosed, on February 22, 2026, Gilead entered into an Agreement and Plan of Merger (the “ Merger Agreement ”), among Parent, the Company and Ravens Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (“ Purchaser ”). In accordance with the terms of the Merger Agreement, on April 28, 2026, Gilead completed the acquisition of the Company. Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, on March 6, 20…
mna activitypositivescore 41 - 2026-04-2810d agoItem 7.01
Regulation FD Disclosure. On April 28, 2026, Gilead Sciences, Inc., a Delaware corporation (“ Parent ” or “ Gilead ”), issued a press release announcing the completion of the acquisition of the Arcellx, Inc., a Delaware corporation (the “ Company ”), a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. The information in
mna activitypositivescore 41 - 2026-02-232mo agoItem 1.01
Entry into a Material Definitive Agreement Agreement and Plan of Merger On February 22, 2026, Gilead Sciences, Inc., a Delaware corporation (“ Parent ” or “ Gilead ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”), among Parent, Arcellx, Inc., a Delaware corporation (the “ Company ”), and Ravens Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Purchaser ”). Pursuant to the Merger Agreement, and upon the terms and subject to the conditions…
mna activitypositivescore 12 - 2026-02-232mo agoItem 7.01
of this Current Report on Form 8-K, including the information incorporated by reference from Exhibit 99.1 hereto this report, shall not be deemed to be incorporated by reference in the filings of the Company under the Securities Act of 1933. Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements related to Gilead, Arcellx and the acquisition of Arcellx by Gilead that are subject to risks, uncertainties and other factors. All statements other than statem…
mna activitypositivescore 9
Score history
The composite score, snapshot by snapshot. The dotted line at zero separates leaning-positive from leaning-negative.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.